News
Novo Nordisk warns copycat drugs continue weighing on sales
Novo Nordisk (NVO) offered investors an update about ongoing cost-cutting efforts as copycat weight-loss drugs weigh on sales and lawmakers push for lower prices. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani outlines the latest and shares what she learned from her interview with Novo Nordisk CFO Karsten Munk Knudsen.
Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.
Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs.
Novo Nordisk previously sued several businesses for allegedly selling copycat versions of its blockbuster weight loss drug Wegovy and popular diabetes shot Ozempic. Now, the Danish drugmaker ...
Investor's Business Daily on MSN3d
Novo Nordisk Slumps As 'Unlawful' Knockoffs Pressure Wegovy, OzempicNovo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results